Assessing the commercial potential of an asset in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Making informed clinical and commercial decisions can help to optimize the value of an asset for pharmaceutical companies. SmartAnalyst was approached with the task of assessing a product in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the US, EU5, and Japan.
SmartAnalyst was challenged to identify potential market and product-related drivers and quantify which assumptions might be associated with identified drivers. Adopting a two-stage approach, SmartAnalyst looked at the current disease and market landscape before conducting a Quantitative Survey to assess the potential of the asset.
SmartAnalyst generated plausible commercial scenarios based on product attributes and market access considerations to inform product development.
Read the full case study here.
Jump to a slide with the slide dots.
Inizio Engage increase access to HPV & MMR vaccinations with mobile vaccination capability
Our Inizio Engage UK nursing team collaborated with Central Liverpool Primary Care Network to pilot a vaccination service, protecting young women...
Read moreDelivering an immersive interactive MOA congress engagement
Our client was new to the complement system space and was preparing to launch an oral, first-in-class medication in a rare blood disease.
Read moreCo-creating an expansive and innovative multichannel medical education program
A top 10 pharma company wanted dermatologists to own the conversation on PsA, and become confident in diagnosing the disease.
Read more